Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/164800 |
Resumo: | Anesthetics are an indispensable prerequisite for surgical intervention and pharmacological animal studies. The objective of present study was to optimize the dose of ketamine (K) and xylazine (X) along with atropine sulfate (A) in order to achieve surgical tolerance in BALB/c mice. Several doses of ketamine (100, 150, 200 mg/kg) and xylazine (10, 15, 20 mg/kg) were mixed and combination of nine doses (K/X: 100/10, 100/15, 100/20, 150/10, 150/15, 150/20, 200/10,200/15,200/20) were evaluated (n=9 per combination). A constant dose of atropine (0.05 mg/kg) was also used to counter side effect. Timerelated parameters were evaluated on the basis of reflexes. KX at dose 200/20 mg/kg produced surgical tolerance in all nine mice with duration 55.00±6.87 minutes. The induction time 0.97±0.09 minutes, sleeping time 90.67±5.81 minutes and immobilization time (102.23±6.83 minutes) were significantly higher than all combination. However, this combination was considered unsafe due to 11 % mortality. While, KX at dose 200/15 mg/kg results in none of the mortality, so was considered as safe. Moreover, this combination produces surgical tolerance in 89 % mice with duration (30.00±7.45 minutes). It was concluded that KX at dose 200/15 mg/kg along with atropine 0.05 mg/kg is safe for performing surgical interventions in BALB/c mice. |
id |
USP-31_26e2a43bc18db1e69ad1d3191cb90965 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/164800 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c miceKetamine hydrochlorideXylazine hydrochlorideAtropine sulfateSurgical toleranceBALB/c miceAnesthetics are an indispensable prerequisite for surgical intervention and pharmacological animal studies. The objective of present study was to optimize the dose of ketamine (K) and xylazine (X) along with atropine sulfate (A) in order to achieve surgical tolerance in BALB/c mice. Several doses of ketamine (100, 150, 200 mg/kg) and xylazine (10, 15, 20 mg/kg) were mixed and combination of nine doses (K/X: 100/10, 100/15, 100/20, 150/10, 150/15, 150/20, 200/10,200/15,200/20) were evaluated (n=9 per combination). A constant dose of atropine (0.05 mg/kg) was also used to counter side effect. Timerelated parameters were evaluated on the basis of reflexes. KX at dose 200/20 mg/kg produced surgical tolerance in all nine mice with duration 55.00±6.87 minutes. The induction time 0.97±0.09 minutes, sleeping time 90.67±5.81 minutes and immobilization time (102.23±6.83 minutes) were significantly higher than all combination. However, this combination was considered unsafe due to 11 % mortality. While, KX at dose 200/15 mg/kg results in none of the mortality, so was considered as safe. Moreover, this combination produces surgical tolerance in 89 % mice with duration (30.00±7.45 minutes). It was concluded that KX at dose 200/15 mg/kg along with atropine 0.05 mg/kg is safe for performing surgical interventions in BALB/c mice.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2019-12-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/16480010.1590/s2175-97902019000317231Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e17231Brazilian Journal of Pharmaceutical Sciences; v. 55 (2019); e17231Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e172312175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/164800/157982Copyright (c) 2019 Brazilian Journal of Pharmaceutical Scienceshttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessJamal, Muhammad AmeenAhmed, Arslan MahmoodTahir, MuhammadAshraf, MuhammadSattar, AbdulGhafoor, AamirMunir, ShahzadAhmed, IrfanHussain, MubashirRiaz, Amjad2021-01-11T18:46:31Zoai:revistas.usp.br:article/164800Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2021-01-11T18:46:31Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice |
title |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice |
spellingShingle |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice Jamal, Muhammad Ameen Ketamine hydrochloride Xylazine hydrochloride Atropine sulfate Surgical tolerance BALB/c mice |
title_short |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice |
title_full |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice |
title_fullStr |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice |
title_full_unstemmed |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice |
title_sort |
Safety and efficacy of ketamine xylazine along with atropine anesthesia in BALB/c mice |
author |
Jamal, Muhammad Ameen |
author_facet |
Jamal, Muhammad Ameen Ahmed, Arslan Mahmood Tahir, Muhammad Ashraf, Muhammad Sattar, Abdul Ghafoor, Aamir Munir, Shahzad Ahmed, Irfan Hussain, Mubashir Riaz, Amjad |
author_role |
author |
author2 |
Ahmed, Arslan Mahmood Tahir, Muhammad Ashraf, Muhammad Sattar, Abdul Ghafoor, Aamir Munir, Shahzad Ahmed, Irfan Hussain, Mubashir Riaz, Amjad |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Jamal, Muhammad Ameen Ahmed, Arslan Mahmood Tahir, Muhammad Ashraf, Muhammad Sattar, Abdul Ghafoor, Aamir Munir, Shahzad Ahmed, Irfan Hussain, Mubashir Riaz, Amjad |
dc.subject.por.fl_str_mv |
Ketamine hydrochloride Xylazine hydrochloride Atropine sulfate Surgical tolerance BALB/c mice |
topic |
Ketamine hydrochloride Xylazine hydrochloride Atropine sulfate Surgical tolerance BALB/c mice |
description |
Anesthetics are an indispensable prerequisite for surgical intervention and pharmacological animal studies. The objective of present study was to optimize the dose of ketamine (K) and xylazine (X) along with atropine sulfate (A) in order to achieve surgical tolerance in BALB/c mice. Several doses of ketamine (100, 150, 200 mg/kg) and xylazine (10, 15, 20 mg/kg) were mixed and combination of nine doses (K/X: 100/10, 100/15, 100/20, 150/10, 150/15, 150/20, 200/10,200/15,200/20) were evaluated (n=9 per combination). A constant dose of atropine (0.05 mg/kg) was also used to counter side effect. Timerelated parameters were evaluated on the basis of reflexes. KX at dose 200/20 mg/kg produced surgical tolerance in all nine mice with duration 55.00±6.87 minutes. The induction time 0.97±0.09 minutes, sleeping time 90.67±5.81 minutes and immobilization time (102.23±6.83 minutes) were significantly higher than all combination. However, this combination was considered unsafe due to 11 % mortality. While, KX at dose 200/15 mg/kg results in none of the mortality, so was considered as safe. Moreover, this combination produces surgical tolerance in 89 % mice with duration (30.00±7.45 minutes). It was concluded that KX at dose 200/15 mg/kg along with atropine 0.05 mg/kg is safe for performing surgical interventions in BALB/c mice. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-12-05 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/164800 10.1590/s2175-97902019000317231 |
url |
https://www.revistas.usp.br/bjps/article/view/164800 |
identifier_str_mv |
10.1590/s2175-97902019000317231 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/164800/157982 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2019 Brazilian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2019 Brazilian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e17231 Brazilian Journal of Pharmaceutical Sciences; v. 55 (2019); e17231 Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e17231 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222914505605120 |